| scholarly article | Q13442814 |
| P50 | author | Jacob Thompson | Q56837061 |
| Dane K Larsen | Q57125177 | ||
| Margaret Alexander | Q57125216 | ||
| Matthew Williams | Q57424282 | ||
| June L Round | Q87779262 | ||
| Warren Voth | Q89444344 | ||
| Marah C Runtsch | Q91619750 | ||
| Thomas B Huffaker | Q106584674 | ||
| Andrew G Ramstead | Q106585015 | ||
| P2093 | author name string | Ruozhen Hu | |
| Ryan M O'Connell | |||
| Soh-Hyun Lee | |||
| William W Tang | |||
| Jared A Wallace | |||
| P2860 | cites work | MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development | Q24620604 |
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder | Q24649158 | ||
| A viral microRNA functions as an orthologue of cellular miR-155 | Q24652947 | ||
| MicroRNA-155 is induced during the macrophage inflammatory response | Q24683841 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| The widespread regulation of microRNA biogenesis, function and decay | Q28131796 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors | Q29619686 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth | Q34899627 | ||
| miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. | Q34985536 | ||
| MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta | Q35011103 | ||
| Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism | Q35044328 | ||
| Immune microenvironments in solid tumors: new targets for therapy | Q35642044 | ||
| miR-155 regulates IFN-γ production in natural killer cells | Q35885288 | ||
| Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp | Q36375152 | ||
| Interleukin-7 receptor expression: intelligent design | Q36720948 | ||
| miR-155-deficient bone marrow promotes tumor metastasis | Q37107054 | ||
| MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression | Q37172065 | ||
| MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer | Q37210788 | ||
| Physiological and pathological roles for microRNAs in the immune system | Q37680666 | ||
| IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis | Q38007051 | ||
| miR-155: an ancient regulator of the immune system | Q38095500 | ||
| Role of miR-155 in the regulation of lymphocyte immune function and disease. | Q38168572 | ||
| Tumor-associated macrophages: from mechanisms to therapy | Q38230880 | ||
| Tumor-associated macrophages as major players in the tumor microenvironment | Q38240110 | ||
| Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting | Q38320111 | ||
| MicroRNAs as regulatory elements in immune system logic | Q38819277 | ||
| Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity | Q39234961 | ||
| miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation | Q42631760 | ||
| T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. | Q42687667 | ||
| A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. | Q43787598 | ||
| MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells | Q47035958 | ||
| The earliest thymic progenitors for T cells possess myeloid lineage potential. | Q50796225 | ||
| Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential. | Q51014847 | ||
| Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155 | Q84620188 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 18530-18541 | |
| P577 | publication date | 2017-09-14 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade | |
| P478 | volume | 292 |
| Q90166586 | Deconvolution of transcriptomes and miRNomes by independent component analysis provides insights into biological processes and clinical outcomes of melanoma patients |
| Q58733261 | Effects of allergic stimulation and glucocorticoids on miR-155 in CD4 T-cells |
| Q89788065 | Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade |
| Q90435682 | Interferon gamma in cancer immunotherapy |
| Q55339993 | Key questions about the checkpoint blockade-are microRNAs an answer? |
| Q90389771 | LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint |
| Q64100323 | MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells |
| Q90609147 | MicroRNA (miR) dysregulation during Helicobacter pylori-induced gastric inflammation and cancer development: critical importance of miR-155 |
| Q64066398 | MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers |
| Q90479399 | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| Q89836573 | Non-coding RNAs in CD8 T cell biology |
| Q89980594 | Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application |
| Q96609205 | Noncoding RNAs: the shot callers in tumor immune escape |
| Q60949868 | Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8 T Cells in Non-small Cell Lung Cancer |
| Q90243992 | T Cell-Expressed microRNA-155 Reduces Lifespan in a Mouse Model of Age-Related Chronic Inflammation |
| Q89540099 | miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen |
| Q58080415 | miR-155 expression in anti-tumor immunity: the higher the better? |
| Q98465623 | microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy |
Search more.